We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Myhealthchecked Plc | MHC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.00 | 08:00:04 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.00 | 9.63 | 10.00 | 10.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 16/4/2024 21:15 by tia01 ControlMHC are in a strong position financially compared to many companies however there shares have like ABDX have trebled from lows etc while ours continues to fall. Probably and hopefully our board can put some contracts together because have clearly done a deal with ABDX because they eventually intend to have there own brand on all the best lines. MHC need also to expand into other places like Sainsbury’s or Morrisons etc. Boots is a tremendous achievement but unless MHC realise they need more to expand they will continue fall as the market don’t see growth. I believe a company must use its cash when the shares are low and unable to be used as leverage to buys other companies. Especially when valuations all over the market are low cash is king. Time to put Covid revenue to use |
Posted at 18/3/2024 07:55 by tia01 After comparing MHC and ABDX you can’t help notice quite a few points.ABDX market cap over 10m MHC over 6.5m ABDX has around 1.9m MHC has around 8m plus ABDX has a high cash burn and needed fund raises. MHC is prudent and cash in the bank growing. ABDX concentrated on revenue growth. MHC concentrated on cash flow and growth. ABDX main product is salistick MHC has over 20 Products So is ABDX Market Cap of 10m justified! Or is MHCs 6.5m way undervalued! Hopefully end of year results will show growth for MHC and we push up to levels of our competitors to reflect the facts. |
Posted at 14/3/2024 09:09 by tia01 A company I mentioned recently called ABDX which has great products and is in a similar space as MHC has had great news this morning and rocketing. I feel MHC could benefit from working with them. The strange thing is they have a salistick product which is a pregnancy test!. That’s where MHC started. Let’s hope we can have positive news and have a run like that.We have cash but ABDX had a strategy of revenue growth but cash position not that great. |
Posted at 02/3/2024 21:33 by tia01 Could ABDX be vulnerable to a takeover given share price keeps falling and the cash burn rate.They could be potentially be a good fit for MHC who has cash and knowledge of the pregnancy test market which ABDX has developed a great product in. Maybe not a direct takeover but some sort of collaboration. MHC would be able to expand its product base into various places ABDX has established itself due to the salistick it’s developed. This one catching my eye because it’s burning cash whilst concentrating on revenue over profit. It finance situation makes it a takeover target or a strategic alliance candidate for someone like MHC |
Posted at 21/2/2024 19:37 by tia01 Black horseWithout being disrespectful but Money obviously moving to MHC which is why we are 50% up from December roughly. Given we are on MHC site I’m happy to discuss money inflowing to MHC. All be it I wish a bit bit quicker lol. The fact is it’s ticking up without any one noticing it so hopefully a good RNS will come and get MHC noticed. I do see resistance at 16-17p if we get there as this was the figure around the time we fell early 2023 when the poor figures landed. I do however feel whilst we have seen a slowdown in covid sales that it’s possible new products are gaining traction. I do think a explanation as to why some of the good likes like intolerance tests are out of stock for so long online but can only assume that potential buyers will still go to stores nearby or use MHCs site directly. I feel the next set of results will be a much better set than lasts years. More cash in the bank and I have a sneaky feeling we are probably going to drop news on a few new products in my opinion. Also need a plan to move more expensive ones otherwise you have to judge if production costs are worth it in the sales figures given they have shelf life expiring dates. Also is MHC a takeover target with cash situation and no debts. I just wonder why Directors not buying and wonder if they are excluded because they are privileged to News coming. All my own personal beliefs but hopefully something soon to take it up to the next level and back to 25p plus as Spacedust said |
Posted at 08/2/2024 00:09 by tia01 The agreement was for the products to go in 801 stores and whether Boots or MHC at fault it’s something that needs addressing.MHC is a small company trying to prove itself and customers wishing to buy the product won’t blame Boots but simply look elsewhere. It’s up to MHC to be proactive as they need Boots not the other way. Im invested in MHC like most others but running out of your best sellers or good sellers dont sit well for the brand image |
Posted at 31/1/2024 11:48 by tia01 BillyI’m glad your experience was good as mine was also. I’m planning to take more as a middle aged person. I wish to point out the significance of the role of the pharmacist moving forward given our investor meeting hints by Penny. The government have said that they expect the 7 new things that pharmacist can prescribe for will free up 10 million new GP appointments! So based on this how many will MHCs new tests free up and how much in cost saving to the NHS will it save!. It’s clearly a positive sign that the government are aware that this is the way forward and MHC compliance with all the requirements and digital data suggests they believe it also. This would increase the sales of more expensive tests whilst the basic ones will fly. Boots in conjunction with MHC have the facilities in place and the benefits to the NHS are clear. I strongly advise people to revisit the investors meeting and Pick up on Penny’s remarks and also her respect to ensuring she doesn’t divulge Boots plans. Also our share price is stagnant which is totally annoying but we must remain positive as any RNS and we could see a significant move. The news today whilst doesn’t directly affect us does point to the way forward and deal with Boots paying dividend shortly. |
Posted at 11/1/2024 14:29 by smithie6 What's the story here ?If I post some bear points is anyone willing to reply & point out why I'm wrong. Some Bear pts 1) the biggest (or almost only) selling product is a COVID test made by someone else & bought by MHC. That has many negative effects. 2) MHC appears to be a middleman in the supply of COVID tests. .that doesn't add any value....& hence there is a high risk imo of MHC being cut out of the chain 3) the margin that MHC makes on COVID tests is pathetic, 15% !! Shop margins are much higher than this. No business can stay listed on AIM making just 15% margin on sales which are not that high & support all the costs of the company. 4) the sales of COVID tests in any 1 year is a complete unknown, a bit like the wind or rain; which is not good for investing. 5) the products put with Boots appear not to have sold in any material volume. |
Posted at 23/12/2023 10:57 by tia01 MHC has the contract to Supply Flowflex to Boots and Lloyds. That’s all so we are the middle person.The cash in the bank is amazing for a small company and I’m also surprised a larger company ain’t snapped MHC up on a cash shell basis also given they also have over 20 products. That said Penny is building a stand alone company which is why they are investing in digital data. 2024 could be a great year for MHC if they manage to survive without being taken over. The thing is what price would someone have to pay. Most investors over 70% down. Mercia own the largest number of shares and wouldn’t accept anything less!!!!. Remember it went to 7p pre consolidation with a 15-1 consolidation. That’s was with no products. That valued it at £1.10p in today’s market. They had a share raise which shareholders were excluded from as I believe Mercia etc underwrote it!. Since then they have 5m in the bank and over 20 products and possibly 7-8m in the bank now and even receiving 5% interest on capital in the bank. The balance sheet is strong and no need for a cash injection so any buyer would need to pay a premium. So the question is what is the true valuation! I would say we get a better picture after Januarys trading update but I suspect 10x current valuation is reasonable if growth can be maintained and new product sales ramped up. Given the potential for ramping up sales such as more contracts,possible deals with GPs etc given HIW and others I potentials like insurance companies and Gyms etc the expansion opportunities are huge. The financial position in a high inflation and interest rate environment is so healthy for MHC they may even make a play for a larger company themselves to expand. They are truly in a perfect place but 2024 is year to truly establish its foothold in the wellbeing market. I’ve used the products and truly believe it’s the way given the NHS is in such a mess. We also paved the way for dividends!. At these prices I could see any investor in for long term getting dividends equal to share price in ten years if growth goes to plan. I seen this with Taylor Wimpy when they collapsed to 4p in 2008 and now nearly £1.50p and dividends more than the price in 2008. This is easily foreseeable for MHC but growth projections in next update is key to 2024. Selling now is suicidal but each to their own and I’m accumulating for a long term and happy to sit tight and regularly top up. Even though I’m currently down like others it’s about investing not gambling and the figures are satisfying despite blip early 2023. Watch the surprise to the second half catch the markets off gaurd |
Posted at 27/11/2023 22:22 by dual TIA - these days people are happy to scan a QR code and order online. Just imagine if MHC had posters in coffee shops or pubs promoting their intolerance & sensitivities test. That would generate good revenue for MHC. That is just one of their products they can market in this way.Also it is not just the NHS just imagine if they strike a deal with a private health insurance company to supply their General Health Test to their policyholders each year.The potential is huge with the range of test MHC have but will they achieve their potential. LetsGetCheck who a competitor to MHC is valued at $1billion, that works out not 10p but £20 a share for MHC. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
